May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
IOP Lowering Efficacy of Bimatoprost and Latanoprost for the Treatment of Normal Tension Glaucoma
Author Affiliations & Notes
  • R.D. Williams
    Taustine Eye Center, Louisville, KY
  • R. Noecker
    University of Pittsburgh, Pittsburgh, PA
  • M. Dirks
    Black Hills Regional Eye Institute, Rapid City, SD
  • M. Earl
    IMEDS, Riverside, CA
  • Footnotes
    Commercial Relationships  R.D. Williams, Allergan C; R. Noecker, Allergan C; M. Dirks, Allergan C; M. Earl, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1305. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R.D. Williams, R. Noecker, M. Dirks, M. Earl; IOP Lowering Efficacy of Bimatoprost and Latanoprost for the Treatment of Normal Tension Glaucoma . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1305.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:Evaluate the IOP–lowering efficacy of bimatoprost 0.03% and latanoprost 0.005% in patients with normal tension glaucoma (NTG). Methods: Randomized, double–masked, multi–center clinical trial. Patients (n= 60) with a diagnosis of NTG were randomized to either bimatoprost or latanoprost for 3 months. Diurnal IOP measurements (8 AM, 12 noon, and 4 PM) were recorded at each study visit (baseline, and months 1 and 3). In enrolled patients, the mean of the baseline diurnal IOP measurements was < 20 mm Hg, with no measurement > 24 mm Hg and no more than 1 measurement of 23 or 24 mm Hg. Results: There were no significant between–group differences in baseline mean IOP at any time point (P>.221). Both bimatoprost and latanoprost provided significant reductions from baseline IOP at all diurnal measurements (P<.001). After 3 months of treatment, mean IOP reductions from baseline ranged from 2.8 to 3.8 mm Hg (18%–22%) with bimatoprost and from 2.1 to 2.6 mm Hg (13%–16%) with latanoprost. The overall mean reduction in IOP after 3 months of treatment was 3.4 mm Hg (20%) with bimatoprost and 2.3 mm Hg (15%) with latanoprost (P=.035). There were no significant between–group differences in adverse event incidence, clinical success, or demographic variables. Conclusions: The overall mean IOP reductions were statistically significantly greater with bimatoprost than with latanoprost. IOP lowering has been proven to reduce the risk of glaucomatous progression in patients with NTG. Results from this study demonstrate that both bimatoprost and latanoprost provide effective IOP lowering, even in the absence of abnormally elevated IOP at baseline. Both bimatoprost and latanoprost effectively reduced IOP in patients with NTG.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×